Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
Sponsor: University of Maryland, Baltimore
Summary
The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's
Official title: Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-08-07
Completion Date
2027-03
Last Updated
2025-08-24
Healthy Volunteers
No
Conditions
Interventions
Semaglutide
The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
Placebo
Patients randomized to placebo arm will receive placebo injection every week.
Locations (2)
Institute of Human Virology at the University of Maryland School of Medicine
Washington D.C., District of Columbia, United States
Institute of Human Virology at the University of Maryland School of Medicine
Baltimore, Maryland, United States